NEW YORK, February 9, 2017 /PRNewswire/ --
Four Medical Appliances and Equipment companies have been lined-up byStock-Callers.com for assessment this morning: Edwards Lifesciences Corp. (NYSE: EW), Accuray Inc. (NASDAQ: ARAY), Hologic Inc. (NASDAQ: HOLX), and Zimmer Biomet Holdings Inc. (NYSE: ZBH). These stocks belong to the Healthcare sector which was mixed
On Wednesday, shares in California headquartered Edwards Lifesciences Corp. recorded a trading volume of 1.78 million shares. The stock ended at $90.83, rising 0.13% from the last trading session. The Company's shares are trading below their 50-day moving average by 1.35%. Furthermore, shares of Edwards Lifesciences, which provides products and technologies to treat structural heart disease and critically ill patients worldwide, have a Relative Strength Index (RSI) of 40.94.
On February 01st, 2017, Edwards reported that sales for Q4 2016 were $767.7 million, up compared to sales of $671.1 million in Q4 2015. The Company's net income for Q4 2016 was $158.5 million, $0.73 per share, or $0.75 per share on an adjusted basis. For Q4 2016, the Company reported Transcatheter Heart Valve Therapy sales of $432.0 million, a 29.2% growth rate on a y-o-y basis.
On February 02nd, 2017, research firm Leerink Partners downgraded the Company's stock rating from 'Outperform' to 'Market Perform'. Visit us today and access our complete research report on EW at:
California headquartered Accuray Inc.'s stock finished yesterday's session 1.75% lower at $5.60 with a total trading volume of 590,382 shares. The Company's shares have gained 12.00% in the last one month, 16.67% over the previous three months, and 21.74% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 9.72% and 5.49%, respectively. Furthermore, shares of Accuray, which designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body, have an RSI of 57.26.
On February 08th, 2017, Accuray announced that it has received Shonin approval from the Japanese Ministry of Health, Labor and Welfare to market its Radixact™ Treatment Delivery System, Accuray Precision™ Treatment Planning System and iDMS™ Data Management System. This new Radixact™ platform is now available in Japan, in certain markets in the European Union (EU), and in the US market. The complimentary report on ARAY can be downloaded at:
At the closing bell on Wednesday, shares in Massachusetts headquartered Hologic Inc. saw a slight drop of 0.43%, ending the day at $39.16. The stock recorded a trading volume of 2.05 million shares. The Company's shares have advanced 1.24% in the previous three months. The stock is trading 4.61% above its 200-day moving average. Moreover, shares of Hologic, which develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the US, Europe, the Asia-Pacific, and internationally, have an RSI of 42.66.
On January 18th, 2017, research firm Deutsche Bank initiated a 'Buy' rating on the Company's stock, with a target price of $48 per share.
On February 02nd, 2017, Hologic announced the launch of its next-generation NovaSure® ADVANCED global endometrial ablation system in the US. The system has been FDA approved. The NovaSure system is designed to reduce abnormal uterine bleeding by applying radiofrequency energy to the endometrium, gently ablating the lining of the uterus in two minutes or less. Register for free on Stock-Callers.com and access the latest research report on HOLX at:
Indiana headquartered Zimmer Biomet Holdings Inc.'s stock ended the day 0.81% lower at $117.15 with a total trading volume of 1.01 million shares. The Company's shares have gained 9.49% in the last month, 12.42% over the previous three months, and 13.52% on an YTD basis. The stock is trading 8.21% above its 50-day moving average. Additionally, shares of Zimmer Biomet Holdings, which together with its subsidiaries, provides musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia/Pacific, have an RSI of 62.39.
On February 01st, 2017, research firm RBC Capital Markets reiterated its 'Outperform' rating on the Company's stock with an increase of the target price from $130 a share to $133 a share.
On February 07th, 2017, Zimmer Biomet announced the international release of the Subchondroplasty® (SCP®) Procedure. The Company received CE Mark approval for the commercialization of its SCP® Procedure to facilitate distribution in the European Union and other countries that recognize the CE Mark. The SCP® Procedure is a minimally invasive outpatient intervention that addresses the defects associated with subchondral bone marrow lesions. Get free access to your research report on ZBH at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Merkel cell carcinoma is a rare and a highly aggressive primary skin cancer that grows rapidly and ...
Vitrectomy is a surgical procedure performed to remove a part or whole of the vitreous humor ...
Boosting metabolism is what you might need to pump your weight loss regime. Slow body metabolism ...View All